Research

Dr. Erin Tagai received a 2022 KCA Psychosocial Focus Award for her research on "Improving patient-reported outcomes for renal cancer patients on active surveillance." Dr. Tagai is an Assistant Research Professor at Fox Chase Cancer Center in Philadelphia, Pennsylvania and a health services researcher focused on the development and implementation of clinic-based strategies to improve patient-reported outcomes across the cancer…

Dr. David Braun received a 2022 KCA Trailblazer Award for his research on “Dissecting the immunobiology of chromophobe renal cell carcinoma using single-cell transcriptomics." Dr. Braun is a medical oncologist and an Assistant Professor of Medicine, Pathology, and Urology, and the Goodman and Gilman Yale Scholar at the Yale School of Medicine. We spoke with Dr. Braun about his work…

Dr. Srinivas Viswanathan received a 2022 KCA Trailblazer Award for his research on "Advancing a Cell Surface Therapeutic Target in Translocation Renal Cell Carcinoma. Dr. Viswanathan is a medical oncologist at the Dana-Farber Cancer Institute. We spoke with Dr. Viswanathan about his work and the impact it can have on people with kidney cancer. Can you summarize your research study?…

Dr. Pooja Ghatalia received a 2022 KCA Trailblazer Award for her research on "Comparison of immune microenvironment between patients of African and European ancestry with renal cell carcinoma." Dr. Ghatalia is a medical oncologist and researcher at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She previously received a KCA research grant in 2017. We spoke with Dr. Ghatalia about her…

Dr. Nazli Dizman received a 2022 KCA Trailblazer Award for her research on the "Impact of CBM588 on metabolomic profile in patients with metastatic renal cell carcinoma (mRCC)". Dr. Dizman is an internal medicine resident at the Yale University School of Medicine. We spoke with her about her work and the impact it can have on people with kidney cancer. What…

By D’Ann George, PhD, Medical Writer https://www.kidneycancer.org/explore-your-treatment-options/ Three separate phase III clinical trials showed that people with kidney cancer who had undergone nephrectomy (kidney removal) but whose cancer had not yet metastasized, or spread, did not benefit from adjuvant immunotherapy.  The trials were testing the theory that adjuvant immunotherapy, which is given after surgery to prevent cancer from returning, might…

By D’Ann George, PhD, Medical Writer https://www.youtube.com/watch?v=dUJDnoEfb0A Dr. Toni Choueiri discusses the COSMIC-313 trial. At the recent European Society of Medical Oncology congress in Paris, oncologists eagerly awaited results from the ground-breaking phase III COSMIC-313 trial for two reasons:  it tested the effectiveness of a three-drug combination - cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) - for the first…

We rounded up a few research highlights from the 2022 Congress of the European Society for Medical Oncology (ESMO), held recently in Paris, France. Pembrolizumab/lenvatinib combo could be frontline treatment for non-clear cell RCC Findings from the phase II KEYNOTE-B61 trial showed combination treatment with pembrolizumab (Keytruda) and lenvatinib (Lenvima) led to greater treatment response and disease control in people with…

Welcome to our series on "Clinical Perspectives." Read the introduction. Dr. Daniel George By D’Ann George, PhD, Medical Writer In the old paradigm, based on chemotherapy, when a tumor grew while being treated with a drug, that meant the drug was no longer working to control the cancer and that was it. Time to move on to another approach —…

By Dr. Daniel GeorgeChair, KCA Medical Steering CommitteeMedical Oncologist, Duke University There is much more to managing kidney cancer than what guidelines say or what clinical trials can test. That’s why we’ve launched a new blog series. Clinical Perspectives will feature current practice trends from nationally recognized experts who treat people with kidney cancer every day. I’m excited to share…